Medications for Chronic Inflammatory Demyelinating Polyneuropathy
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Chronic Inflammatory Demyelinating Polyneuropathy.
Found 1 Approved Drug for Chronic Inflammatory Demyelinating Polyneuropathy
Efgartigimod
Brand Names
VYVGART Hytrulo, Vyvgart
Efgartigimod
Brand Names
VYVGART Hytrulo, Vyvgart
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 17, 2021
Classification: Neonatal Fc Receptor Blocker
VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP) VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive ( 1 ) chronic inflammatory demyelinating polyneuropathy (CIDP) ( 1 )
Showing 1-1 of 1
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances